Even though renal cell carcinomas (RCC) are thought to be immunogenic, many tumors express variations in surface molecules and intracellular proteins that hinder induction of optimal antitumor responses. Interferon gamma (IFN␥) stimulation can correct some of these deficiencies. Therefore, we introduced the complementary DNA (cDNA) encoding human IFN␥ into a well-characterized RCC line that has been selected for development of an allogeneic tumor cell vaccine for treatment of patients with metastatic disease. Studies were performed to determine how endogenous IFN␥ expression influences tumor cell immunogenicity. IFN␥ transductants showed minimal increases in surface expression of MHC class I and adhesion molecules but
Introduction
Currently, there is much interest in using genetically engineered tumor cells to enhance antitumor immune responses. Tumor cells can be altered genetically either in vivo or ex vivo to express new MHC molecules, adhesion molecules or costimulatory molecules.
1,2 They can also be modified to express cytokines that influence immune responses. [3] [4] [5] Following vaccination with genetically engineered tumor cells or introduction of such genes into tumors in vivo, activated lymphocytes should develop that are able to recognize and destroy unmodified tumor cells. Animal tumor models have proved this approach to be valid. 3, 5 There is good reason to hope that such strategies may be of clinical benefit in renal cell carcinomas (RCC) since there is evidence that some patients can expression of class II molecules was induced. Proteins of the transporter associated with antigen processing (TAP) and low molecular weight polypeptide (LMP) were constitutively expressed at high levels. The transductants stimulated allospecific cytotoxic T lymphocytes (CTL); however, they were not better than unmodified tumor cells in this capacity. Endogenous IFN␥ expression enhanced tumor cell recognition by MHC-restricted, tumor antigen-specific CTL but suppressed recognition by non-MHC-restricted cytotoxic cells. Thus, the functional consequences of IFN␥ expression varied with respect to the type of effector cell and were not always beneficial for tumor cell recognition. Gene Therapy (2000) 7, 950-959.
respond immunologically to their tumors; spontaneous tumor regression has been documented in a number of cases and tumor regression was induced in some patients treated systemically with cytokines or interferons (reviewed in Ref. 6) .
The nature of immune responses that lead to RCC regression are poorly understood. Various cytotoxic effector cell types have been identified in patients with RCC that are capable of recognizing and destroying autologous tumor cells (reviewed in Ref. 7) . One type that is prevalent among tumor-infiltrating lymphocyte (TIL) populations of many RCC patients shows a non-MHCrestricted pattern of specificity. Such T cells lyse not only autologous tumor cells but also a variety of allogeneic tumor cells, seemingly irrespective of MHC sharing. In fact, a prominent characteristic of these T cells is their ability to recognize the Daudi cell line which does not express MHC class I molecules. [8] [9] [10] [11] A similar cytotoxic population can be generated by culturing peripheral blood lymphocytes (PBL) with high levels of recombinant interleukin-2 (IL-2) to generate lymphokine-activated killer (LAK) cells. Both CD3
− and CD3 + LAK cells show non-MHC-restricted specificity. 12, 13 While the molecular basis of tumor cell recognition by these effector cell types remains to be defined it has been found that the adhesion molecules ICAM-1 (CD54) and leukocyte-associated function molecule 3 (LFA-3, CD58) are important for optimal effector-target cell interactions. [14] [15] [16] More rarely, classical MHC-restricted CTL have been identified in RCC patients. [17] [18] [19] [20] [21] [22] [23] [24] CTL lysis of autologous tumor cells is dependent upon triggering of their T cell receptors (TCR) with a ligand composed of a tumor-associated peptide complexed with an MHC molecule. 25, 26 Interferon gamma (IFN␥) has several important immune modulating capacities that might contribute to the optimal development of both types of antitumor response in RCC patients. It can induce expression of MHC class II molecules in epithelial cells that do not constitutively express such molecules. [27] [28] [29] This in turn enables their interaction with CD4
+ cells that supply cytokines, like IL-2, that support the development of both types of cytotoxic effector cell. IFN␥ can up-regulate the expression of MHC class I molecules and adhesion molecules, including ICAM-1 and LFA-3, that are important in effector cell-target cell interactions mediated by both MHC-restricted and non-MHC-restricted effector cells. 14, 16, 30 It also increases transcription of the TAP and LMP genes. 31, 32 These genes encode proteins that play critical roles in the processing and presentation of endogenous peptides by MHC class I molecules, thereby improving ligand presentation for MHC-restricted CTL. 33, 34 These properties make IFN␥ an interesting candidate for inclusion in genetically engineered tumor cell vaccines. Genetic modification of murine fibrosarcomas and human melanomas to express IFN␥ was shown to enhance immunogenicity for T cells but to be detrimental for NK cell recognition. [35] [36] [37] [38] Introduction of IFN␥ into other tumor lines did not improve responses and could even be detrimental to the tumor host. 39, 40 Therefore, it is important to evaluate directly how IFN␥ modification impacts on various immune cells directed against a given tumor type, particularly if clinical application is foreseen.
Results
Generation of IFN␥ transductants using the RCC-26 tumor cell line In order to assess the feasibility of using an allogeneic tumor cell vaccine for patients with metastatic RCC we carried out extensive analyses of effector-tumor cell interactions using various RCC lines. The RCC-26 cell line was selected for further development because it was found to be recognized by MHC-restricted CTL derived from different RCC patients, demonstrating that it expressed several distinct immunogenic epitopes 7 (and unpublished data). T cells recognizing one HLA-A2-restricted ligand were found to utilize highly characteristic T cell receptors (TCR), providing a molecular marker to track the development of CTL responses 41 and earlier genetic engineering of this cell line to express human recombinant IL-2 showed that strong enhancement of tumor cell recognition by both MHC-restricted and non-MHC restricted T cells could be achieved. 42 To determine how modification of RCC-26 cells to express IFN␥ would influence immunogenicity, we introduced the cDNA for human IFN␥ into two separate bulk cultures of RCC-26 cells by retroviral transduction using Gene Therapy a vector that was shown previously to generate IFN␥-secreting RCC. 43 The two independently derived cultures were designated as RCC-26/IFN␥1 (endo␥1) and RCC-26/IFN␥2 (endo␥2). A control population (RCC-26VC) carrying the identical vector without the IFN␥ sequence was used for comparison.
Uncloned populations with stable vector integration were selected in bulk by growth in G418-containing medium for extended periods of time. When IFN␥ secretion of the uncloned populations was analyzed by ELISA, no cytokine secretion could be detected (data not shown). Therefore, the bulk cultures were analyzed for the presence of IFN␥ transcripts by RT-PCR. Unmodified tumor cells, RCC-26VC cells and PBL stimulated with 1% PHA for 72 h were included as controls. A band of the expected 226 bp size was found in the PHA-activated PBL but not in unmodified RCC-26 and RCC-26VC cells (Figure 1a) . Bands of expected size were also present in the endo␥1 and endo␥2 transductants, demonstrating that these tumor cells were transcribing the IFN␥ transgene. When template material was generated in the absence of RT, no bands were detected, certifying that the positive PCR signals did not arise due to DNA contamination. IFN␥ protein was also found to be present in the IFN␥ transductants using intracellular immunofluorescence analysis with an antibody specific for IFN␥. The shift in fluorescence intensity, as compared with control tumor cells, indicated that intracellular cytokine was present in the transductants even though its secretion could not be detected by ELISA (Figure 1b) .
These low intracellular cytokine levels were adequate enough to have a regulatory impact on the expression of several molecules in the tumor cells, as assessed by flow (Figure 2c, g ). These levels of class II expression were obtained only when tumor cells were exposed to at least 50 U/ml of exogenous IFN␥ for 96 h, but not through continual exposure of RCC-26 cells to low levels of IFN␥ (1 U/ml, added biweekly over 7 weeks of culture; data not shown). While the endo␥1 and endo␥2 cells only showed levels of MHC class I and ICAM-1 expression here that were comparable with those of the RCC-26VC control cells, some increases in these molecules could be measured in other experiments. Good MHC class II expression was consistently seen in the endo␥1 cells and levels varying from low to high were detected when the endo␥2 cells were analyzed in multiple experiments (Figure 2k , o; and data not shown). Thus, even in the absence of secreted IFN␥, the endo␥1 and endo␥2 lines showed alterations in cell surface expression, indicating functional activity of the transgenes.
Since both cell lines were generated independently and represented uncloned populations they are composed of
Figure 2 Cell surface expression of MHC class I, II and adhesion molecules. RCC-26 (a-d), RCC-26VC (e-h) and the endo␥1 (i-l) and endo␥2 (m-p) cells were tested for expression of class I molecules, HLA-A2 molecules, HLA-DR class II molecules and ICAM-1 expression using the reagents listed in Materials and methods. In RCC-26 and RCC-26VC cells isotype control binding is depicted by the stippled curves (. . . .), specific antibody binding on unstimulated cells by the thin-line curves (--) and cells stimulated with exogenous IFN␥ and stained with specific antibody by the thick-line curves (--). Endo␥1 and endo␥2 cells stained with isotype control antibodies are depicted with stippled curves (. . . .) and with specific antibodies by the thick-line curves (--).
cells with different sites of viral integration. Multiple colonies emerged in each line after initiation of selection in G418-containing medium. The surface expression of MHC and adhesion molecules showed a normal distribution in the transduced lines. Therefore, it is unlikely that the site of viral integration or selection of unique clones accounted for these regulatory effects of IFN␥ in the transductants. Furthermore, such alterations in surface marker expression were not seen when the RCC-26 cells were engineered to express IL-2, 42 interleukin-7 or granulocyte-macrophage colony-stimulating factor (GM-CSF), demonstrating that the changes were due to IFN␥ expression (data not shown).
IFN␥-transduced tumor cells show enhanced TAP and LMP expression LMP and TAP molecules contribute to the amount and quality of MHC-peptide ligands through their influence on the proteolytic processing and transport of peptides. 31, 32 Reduced expression of TAP proteins has been observed in some tumor cells including RCC, providing one mechanism that may allow cells to escape specific T cell recognition. 44, 45 Since IFN␥ has been shown to upregulate transcription of TAP and LMP genes 31, 32 better expression of these molecules could contribute to improved CTL priming and recognition. Therefore, the IFN␥ transductants and exogenously treated tumor cells were compared for expression of TAP1, TAP2, LMP2 and LMP7 proteins in Western blots ( Figure 3 ). Only faint bands for both TAP and LMP proteins were detected in untreated RCC-26 cells but high levels were induced following exogenous IFN␥ stimulation. An equally strong induction of these proteins was seen following exogenous IFN␥ stimulation of RCC-26VC cells (data not shown). The endo␥1 and endo␥2 transductants were found constitutively to express even higher levels of TAP and LMP proteins than those induced by exogenous IFN␥ treatment. Stable, high expression of these proteins was maintained in the transductants over long periods of time (data not shown). Thus, endogenous expression of IFN␥ could dramatically alter deficits in some components of the peptide processing and presentation machinery of the tumor cells.
Unmodified tumor cells and IFN␥-transduced cells induce comparable allospecific CTL responses
The ability of IFN␥-transduced tumor cells to influence immune function was first assessed by analyzing the ability of the tumor cells to induce CTL responses in allogeneic mixed lymphocyte tumor cell cultures (MLTC). PBL of two healthy, control donors were cocultured with either unmodified RCC-26 tumor cells or the endo␥1 cells. The endo␥1 cells were selected for these experiments because they consistently showed better levels of MHC class I and II expression when tested in multiple flow cytometry experiments. Endo␥1 cells were compared as stimulating cells with unmodified tumor cells since this represents the situation that would prevail in a clinical setting. After three rounds of restimulation in MLTC the primed lymphocytes were analyzed for the presence of cytotoxic effector cells using RCC-26, endo␥1, Daudi and K562 as target cells in a 4 h chromium release assay. The results from one donor are shown in Figure 4 ; comparable results were obtained using PBL of the second donor (data not shown). High levels of cytotolytic activity were detected against both RCC-26 ( Figure 4a) 
Figure 4 Induction of allospecific CTL by RCC-26 and endo␥1 cells. Activated PBL isolated from a MLTC using responding lymphocytes of donor JB (HLA-B*5101) were stimulated with (a, c) unmodified RCC-26 cells or (b, d) endo␥1 cells. CTL activity was measured in a standard 4 h chromium release assay using RCC-26 cells (̅), endo␥1 cells (̆), Daudi () and K562 (᭹) cells. The fine specificity of allorecognition was determined using LCL matched for single HLA-A (HLA-A*0201 or *3303) or HLA-B (HLA-B41 or *5101) allotypes with RCC-26 cells.
Gene Therapy and endo␥1 (Figure 4b ) cells. The levels of lysis were somewhat higher for unmodified tumor cells and there was no apparent improvement in CTL generation using the endo␥1 tranductant for stimulation of PBL when compared with unmodified RCC-26 cells. Since only weak levels of nonspecific lysis of Daudi and K562 cells were detected we surmised that these effectors cells represented allospecific CTL. This conclusion was supported by assessing the fine specificity of target cell recognition, whereby the CTL were tested for their ability to recognize allogeneic LCL that shared single HLA-A or B allotypes with RCC-26 cells. Three of the four allogeneic LCL were lysed by the CTL, reflecting recognition of mismatched MHC class I molecules of the responding cell donor and RCC-26 cells. This donor carries the HLA-B*5101 allele, accounting for the lack of development of CTL against this self MHC molecule.
This experiment showed that unmodified as well as IFN␥-transduced tumor cells were able to induce strong responses, representing a spectrum of different allospecificities. However, the endogenous expression of IFN␥ in the tumor cells did not improve the levels of cytolytic activity or alter the fine specificity of the alloresponse induced in the MLTC.
IFN␥ transduction enhances tumor-antigen specific CTL lysis
In a second series of functional experiments the IFN␥ transductants and exogenously stimulated tumor cells were compared as target cells for cytotoxic T cells of patient 26 that were obtained from an autologous tumor infiltrating lymphocyte (TIL) population. TIL-26 cells which were isolated from the primary tumor were shown previously to represent a population of HLA-A2 restricted, tumor antigen-specific CTL. 21 Thus, they lysed RCC-26 cells but not Daudi cells (Table 1) ; they also did not lyse autologous normal kidney cells of patient 26 (NKC-26) and K562 cells. 21 Improved recognition by TIL-26 cells was detected when RCC-26 cells were pretreated with exogenous IFN␥ and tested as target cells in a chromium release assay. The RCC-26VC cells were less well recognized by TIL-26 in this experiment; however, pretreatment with exogenous IFN␥ substantially improved recognition. The endo␥1 and endo␥2 cells were better recognized than the vector control cells, being lysed at levels comparable with or greater than those attained following pretreatment of RCC-26VC cells with 1000 U/ml exogenous IFN␥. The endo␥1 cells were consistently found to be better target cells when compared with endo␥2 cells. The IFN␥-mediated enhancement of lysis was confirmed in six independent experiments (Figure 5a ). The same hierarchy in improved sensitivity to lysis by TIL-26 was observed throughout, showing that exogenously treated tumor cells were most susceptible followed by endo␥1 and endo␥2 cells. The susceptibility to lysis of tumor cells exposed either exogenously to 1000 U/ml IFN␥ or modulated intracellularly by low levels of cytokine was significantly greater than that of untreated control cells.
Since the IFN␥-transduced lines did not secrete measurable cytokine the exogenously stimulated cells were washed free of exogenous cytokine to eliminate any direct influence of IFN␥ on the effector cells. In order to simulate the effects of IFN␥ secretion by tumor cells, we added exogenous IFN␥ to the culture medium during the chromium release assay. The levels of IFN␥ that were added represented a range that would be reached if transduced tumor cells secreted 500-5000 U/ml/10 6 cells. Despite these high relative concentrations of IFN␥ we could not observe significant alterations in the lytic capacity of the CTL. (Table 2) . However, when the tumor lines were pretreated with exogenous IFN␥ they became highly resistant to LAK-mediated cytotoxicity. A similar resistance was found with the endo␥1 and endo␥2 transductants. Addition of exogenous IFN␥ to the culture medium during the 4 h chromium release assay had no influence on the LAK-26 cell activity directed against the untreated tumor cells and it was not able to reverse the IFN␥-induced target cell resistance. The inhibition of tumor cell lysis to LAK-26 cells induced by exogenous and endogenous IFN␥ was confirmed in four independent experiments (Figure 5b) . The endo␥2 cells retained a low, but consistent degree of susceptibility to the non-MHC-restricted LAK cells. However, if they were pretreated with exogenous IFN␥ they became fully resistant to LAK-26 mediated killing (data not shown), suggesting that the level of endogenous IFN␥ might influence target cell resistance. Interestingly, the interpretation that the endo␥2 cells express less endogenous cytokine would be consistent with the observations of a lower increase in MHC class I and class II surface expression as compared with endo␥1 cells (Figure 2) .
A general alteration in target cell sensitivity to cytolytic mechanisms seemed unlikely to explain these results since the IFN␥ transductants were highly susceptible to lysis by allospecific and tumor antigen-specific CTL (see Figure 4 and Table 1 ). The decrease in susceptibility was also not due to some unexpected alteration caused by their genetic manipulation since both unmodified RCC-26 and RCC-26VC showed similar patterns, ie enhanced recognition by TIL-26 and resistance to LAK-26 mediated lysis following exogenous IFN␥ treatment. Target cells were pretreated for 72 h with 1000 U/ml IFN␥ before use in chromium release assay. NT, not tested.
Discussion
In the absence of effective chemotherapies or radiation therapies for RCC recent efforts have been devoted to the development of immunotherapies for treatment of metastatic disease. Systemic application of rIL-2 alone, or in combination with interferon alpha (IFN␣), has been beneficial for some RCC patients. However, clinical benefit is not long lasting and is often accompanied by serious toxicity. 6, [46] [47] [48] One study reported good clinical responses following systemic IFN␥ treatment 49 but similar results have not been seen in other patients. 6, 50, 51 Because of the toxicities associated with systemic interferon application this form of treatment is not suitable for patients with low performance status or as an adjuvant therapy for patients with minimal residual disease. Recent efforts have been directed to the development of vaccines or in vivo transfer of transgenes into tumors to enhance tumor cell immunogenicity. Animal studies revealed that it is particularly important to induce MHC-restricted CD4 + and CD8
+ T cells because they retain a memory potential providing long lasting immunity. [52] [53] [54] [55] On the other hand, non-MHC-restricted cytotoxic cells have been identified as the only source of effector cells in many RCC patients. 18, 56 While their dependence on CD4 + T cell help has not been studied, they are dependent on IL-2. Since it is not known a priori how patients respond to their tumors and how these responses will be altered through vaccination with genetically engineered tumor cells or by introduction of cytokine genes directly into tumor cells in vivo, we felt it important to compare the influence of IFN␥ tumor cell modification on the functional activity of different effector populations, including both MHC-restricted and non-MHC-restricted cytotoxic lymphocytes.
The use of IFN␥ appeared promising because of its multi-faceted potential to influence immune responses through enhanced expression of molecules that contribute to both specific and non-specific effector cell-tumor cell interactions. [57] [58] [59] Indeed, the introduction of the IFN␥ cDNA into our tumor vaccine line enhanced expression of several cellular proteins that should foster improved effector-target cell interactions.
An enhanced recognition of RCC-26 cells by MHCGene Therapy restricted, tumor antigen-specific CTL was seen consistently following exogenous IFN␥ treatment and improved recognition of the IFN␥ transductants was also achieved. IFN␥-induced increases in TAP and LMP could contribute to enhanced target cell recognition through improved peptide ligand generation. The minimal alterations in class I and ICAM-1 expression would not appear to be contributing factors nor does class II expression seem to be revelant here because the CTL are CD8 + and class I restricted. Surprisingly, improved recognition of the transductants was comparable with or greater than that achieved when the vector control cells were prestimulated with 1000 U/ml exogenous IFN␥, even though the transductants did not secrete detectable IFN␥. The alterations in MHC class II expression were not seen in transductants made using the same vector carrying the cDNA encoding IL-2, IL-7 or GM-CSF, demonstrating that modulation was specific for IFN␥ (data not shown). IFN␥ has been found previously to influence gene regulation in other non-secreting cells following its introduction as a transgene; it may exert such regulatory effects intracellularly through a private autocrine loop. 60, 61 In contrast to the enhancement of MHC-restricted CTL recognition, no improvement in the induction of allogeneic CTL or in tumor cell recognition by non-MHCrestricted effector cells could be detected. In fact, this genetic modification led to tumor cell resistance to lysis by both autologous and allogeneic LAK cells. This was not due to a general alteration in the tumor cell lines caused by retroviral transduction since introduction of the cDNA for IL-2 was shown previously to improve susceptibility of RCC-26 cells to both tumor antigen-specific CTL and non-MHC-restricted LAK-26 cells. 42 IFN␥ was shown previously to induce resistance to NK-mediated lysis in other tumor types; in some cases this was ascribed to enhanced MHC class I expression, particularly when unmodified tumor cells expressed low levels of MHC class I molecules. 37, 38, 62, 63 Since RCC-26 cells constitutively express substantial levels of HLA class I molecules, IFN␥ induced only minor increases in class I expression on occasion. Whether alterations in the expression of particular allotypes account for the induced resistance to lysis by non-MHC-restricted T cells remains to be determined.
The results of these functional studies reveal that caution must be taken in assuming that a particular genetic modification will necessarily enhance antitumor immunity. This is particularly critical when the molecular basis of tumor cell recognition is poorly understood, as is often the case in gene therapy protocols using autologous tumor cell vaccines. While the vector used to generate the IFN␥ transductants was successfully employed to develop other RCC lines secreting interferon, despite multiple attempts we were unable to obtain stable IFN␥ secretion from RCC-26 cells. We have noted that exogenous treatment with IFN␥ has a cytostatic effect on RCC-26 cells (data not shown); thus continual exposure may preclude the survival in vitro of transductants secreting IFN␥. When the non-secreting IFN␥ transductants were cultured with exogenous IFN␥ during the chromium release assay to mimic the effect of cytokine secretion, we could not substantially enhance CTL activity nor could the resistance to non-MHC-restricted cells be reversed. Thus, the different functional outcomes appear to be a direct result of alterations in the tumor cells. Therefore, it is conceivable that in vivo application of IFN␥ vectors into RCC could create a situation that allows enhanced MHC-restricted CTL recognition but is detrimental for non-MHC-restricted effector cell activity. We have seen a comparable development of resistance to non-MHCrestricted effector cells in a second RCC line that was genetically engineered to express endogenous IFN␥, revealing that this effect is not unique for RCC-26 cells (data not shown).
In the case of vaccine development utilizing established tumor cell lines that are modified ex vivo, such as our approach using RCC-26 cells, detailed functional studies can be performed to evaluate the impact of genetic modification. Here, it seems particularly important to analyze immune reactivity of various effector cells that may contribute to responses in patients in vivo. Our results suggest that IFN␥ is not a suitable candidate for inclusion in this genetically engineered RCC vaccine. Furthermore, caution is warranted in applying IFN␥ vectors in RCC patients in vivo. The functional consequences of IFN␥ stimulation revealed by our studies may provide some insight into the clinical outcome in RCC patients treated with interferons. 6 While IFN␣ has shown positive clinical benefit in a number of trials, benefit has rarely been achieved with IFN␥. The capacity of IFN␥ to render tumor cells fully resistant to lysis by non-MHC-restricted effector cells, which predominate in many RCC patients, may contribute to this failure. Preliminary studies (data not shown) reveal that no or only minimal inhibition of non-MHC-restricted effector cells (both NK and T cells) is seen when tumor cells are pretreated with IFN␣ in contrast to a full inhibition seen with IFN␥.
Materials and methods

Establishment of tumor cell lines and cytotoxic effector cells
The RCC-26 tumor line was established from a primary carcinoma of a stage I (T1, G2, N0, M0) patient as described 21 and cultured in RPMI 1640 medium supplemented with 2 mm l-glutamine, 1 mm sodium-pyruvate and 10% heat-inactivated fetal calf serum (FCS). These tumor cells were modified to express IFN␥ endogenously by transduction with the human IFN␥ cDNA using the retroviral system described previously. 43 As controls, transductants were made using the same vector without IFN␥ cDNA or carrying instead the cDNA for human rIL-2. 42 PBL obtained at the time of surgery from patients undergoing tumor resection were used for the generation of LAK cells by culture in RPMI 1640 medium supplemented with 2 mm l-glutamine, 1 mm pyruvate, 15% heat-inactivated, pooled human serum, 1% phytohemagglutinin (PHA) and 1000 U/ml rIL-2 (Proleukin; Cetus, Emeryville, CA, USA). TIL were obtained from the primary tumor as described previously, 21 cultured in RPMI 1640 with 7% FCS, 7% heat-inactivated, pooled human serum, 5% conditioned medium obtained from PHA-activated lymphocytes 64 and 25-50 U/ml rIL-2. The tumorspecific CTL were restimulated every 7-10 days with irradiated (100 Gy) autologous tumor cells.
Mixed lymphocyte tumor cultures (MLTC) were established using PBL of healthy control donors and irradiated (100 Gy) tumor cells, plating 0.5 × 10 6 responding cells and 3 × 10 4 irradiated tumor cells per well of a 24-well culture plate. The presence of allospecific CTL was assessed using a panel of Epstein-Barr virus-derived lymphoblastoid cell lines (LCL) that were individually selected to match the tumor cells by only one MHC class I allele.
Generation of RCC transductants
The retroviral vector N2/CMV/IFN␥ has been described previously. 65 It contains the neomycin gene as a selection marker under the control of the Moloney murine leukemia virus long terminal repeat and the cDNA of human IFN␥ driven by the internal cytomegalovirus promoter. Retroviral infection and selection in G418-containing medium was done as described. The RCC lines were continuously maintained in G418-containing medium (0.7 mg/ml).
Exogenous cytokine stimulation and endogenous expression of IFN␥ For exogenous treatment, tumor cells were cultured in medium containing 1000 U/ml of recombinant IFN␥ for 96 h (Dr Rentschler, Biotechnologie GmbH, Laupheim, Germany). A commercial ELISA (sensitivity of 16 pg/ml) (Laboserve, Giessen, Germany) was used to measure IFN␥ in the culture medium of the transduced tumor cells.
Detection of IFN␥ by reverse transcriptase polymerase chain reaction (RT-PCR) was performed using total RNA isolated from 1 × 10 6 cells with RNazol B (Cinna/Biotecx, Houston, TX, USA) and cDNA was synthezised by reverse transcription (Gibco BRL Superscript, Gaithersburg, MD, USA). PCR was performed using oligo-dT primed cDNA and IFN␥-specific oligonucleotides (sense: 5′CAGATGTAGCGGATAATGGA3′; antisense: 5′AGCTT TTCGAAGTCATCTCG3′) starting with 3 min at 95°C, 35 cycles of 1 min at 95°C, 1 min at 60°C, 2 min at 72°C, and finishing with 5 min at 35°C. The 226 bp amplicon was visualized on a 2% agarose gel stained with ethidium bromide.
Intracellular IFN␥ was measured using a cell permeabilization protocol adapted from intracellular cytokine staining of lymphocytes. To enrich the intracellular IFN␥ concentration, tumor cells were cultured for 4 h with Cell-mediated lysis assay Cell-mediated lysis was quantified in a standard 4 h chromium-51 release assay. To compare data from independent cytotoxicity experiments a percent relative cytotoxic response (% RCR) was calculated using the specific lysis of untreated RCC-26 cells in each experiment as a reference value of 50%. The specific lysis of all other target cells in the experiment was determined in relation to the reference value and expressed as a % RCR, as described previously. 66 The mean and standard deviations were calculated and graphically depicted using the Excel 7.0 program.
Indirect immunofluorescence
Tumor cells were tested for surface expression of MHC class I, HLA-A2, HLA-DR, and ICAM-1 by flow cytometry using the following mAb: W6/32 specific for MHC class I molecules (American Type Culture Collection (ATCC), Rockville, MD, USA); L243 specific for HLA-DR (ATCC) and mAb P3.58B specific for ICAM-1 (kindly provided by JP Johnson, Institute of Immunology, University of Munich, Germany). HLA-A2 expression was measured using mAb mA2.1 (ATCC). mAb UPC-10 (Sigma) specific for a mouse myeloma protein was used as a negative control. Cells were incubated with mAb for 90 min on ice, washed twice with PBS and then incubated with fluorescein-isothiocyanate (FITC)-conjugated goat anti-mouse F(ab) 2 -immunoglobulin (F313; Dakopatts) for 30 min. Cells were analyzed using flow cytometery.
Western blot analysis of TAP and LMP using enhanced chemiluminescence (ECL) detection 5 × 10 6 tumor cells were lysed in 100 l TE-buffer (10 mm Tris-HCl, 2 mm EDTA, pH 7.6), supplemented with 3 l of protease inhibitors (1 mm phenylmethylsulfonyl fluoride and 2.5 mm benzamidine) and 100 l of 3 × SDS-PAGE buffer containing ␤-mercaptoethanol. 67 To facilitate lysis the suspension was passed several times through an 18-gauge needle and heated at 37°C for 5 min. Ten l of each sample was separated by 8-18% SDSGene Therapy PAGE. Proteins were transferred to nitrocellulose membranes and visualized by Ponceau staining. The positions of the molecular weight standard proteins were marked. Immunodetection of LMP and TAP proteins was performed using enhanced chemiluminescence (ECL; Amersham, Buckinghamshire, UK) according to the manufacturer's instruction. For the detection of TAP1 and TAP2 proteins, the membranes were incubated overnight at room temperature with either anti-TAP1 mAb 148.3 (1:10 dilution of hybridoma supernatant) 68 or anti-TAP2 mAb 429.3 (1:20 dilution of hybridoma supernatant), 69 followed by a 1 h incubation with a 1:8000 dilution of horseradish peroxidase-conjugated goat anti-mouse polyclonal antibody (A4416; Sigma) at room temperature. After ECL detection the membrane was stripped of bound antibodies by incubation in a solution containing 60 mm Tris-HCl, 2% SDS, 100 mm ␤-mercaptoethanol, pH 6.7 at 50°C for 30 min. The membranes were reprobed using polyclonal antibodies against LMP2 (1:200 dilution of rabbit antiserum) and LMP7 (1:200 dilution of rabbit antiserum) 70 followed by a 1 h incubation with a peroxidase-conjugated polyclonal goat anti-rabbit antibody (A6154; Sigma).
